A Phase 2 interventional study of ozarelix and Placebo in Benign Prostatic Hyperplasia (BPH) and Lower Urinary Tract Symptoms (LUTS), sponsored by Spectrum Pharmaceuticals, Inc. Terminated at 1 site in United States. Open to male participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2021-11-22.
Sponsored by Spectrum Pharmaceuticals, Inc (part of Zydus Lifesciences Limited) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 188 studies in Prostatic Hyperplasia with a site in United States — 29 open to participants now, 48 under way, none of them phase 3. Prostatic Hyperplasia · United States.
Among the 188 studies in Prostatic Hyperplasia with a site in United States, this one is the 112th largest by enrollment of the 150 interventional ones that give a count, is one of 9 that started in 2008, is one of 27 in phase 2, and was the 41st registered.
831 studies on the registry are indexed under Prostatic Hyperplasia; 180 are open to participants now.
Browse Prostatic Hyperplasia studies →29 of the 188 studies in Prostatic Hyperplasia with a site in United States are open now. Recruiting first, the newest first:
ALPFA Medical · Sites in United States
Ages 45+ · Men only
ProVerum Medical · Sites in United States
Ages 45+ · Men only
Zenflow, Inc. · Sites in United States
Ages 18+ · Men only
Northwestern University · Sites in United States
Ages 18–100 · Men only · Healthy volunteers
Northwestern University · Sites in United States
Ages 18–100 · Men only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 103 Prostatic Hyperplasia studies recruiting now, 70 (68%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 50 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
188 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 35 · Phase 3 28 · Phase 4 16
First in 1988; this study’s year is marked. 9 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 28 is below the median of 94 across 629 interventional studies indexed under Prostatic Hyperplasia.
Median enrollment 83 across the 150 interventional studies, 201 across the 37 observational. Of the 121 that completed or were terminated, 58 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
99 of 188 have an industry lead sponsor. The 10 most frequent:
This study is registered under Spectrum Pharmaceuticals, Inc, one of the names counted as Zydus Lifesciences Limited. Under that name alone:
Spectrum Pharmaceuticals, Inc is the lead sponsor of 60 studies on the registry; 1 is open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 12 (67%) have results posted.
Zydus Lifesciences Limited has 2 studies filed under Prostatic Hyperplasia — fewer than ten, so there is no comparison to draw.
14 of the studies in Prostatic Hyperplasia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04288427Beth Israel Deaconess Medical Center5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy | 2026-12-30 |
| NCT05400980Prodeon Medical, IncExpander-2 Trial: Randomized Study to Evaluate Safety & Efficacy of the Urocross® Expander System & Retrieval Sheath | 2027-01 |
| NCT06224218University of Illinois at ChicagoProstate Single Port & Laser Enucleation Comparison Trial | 2027-01-15 |
| NCT06560476Urotronic Inc.OPtilume™ BPH Catheter SystEm for Treatment of Men eXperiencing Symptomatic BPH | 2027-03-30 |
| NCT05898932Northwestern UniversityEnhanced Clinical Decisions for Management of Benign Prostatic Hyperplasia Using Patient-Reported Outcomes | 2027-04 |
Add all 14 to your calendar (.ics) → With an account.
Among the 188 studies in Prostatic Hyperplasia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multi-center, randomized, double-blind, placebo-controlled study to evaluate the efficacy of ozarelix compared to placebo in the treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) in men as assessed by the International Prostate Symptom Score (IPSS) at Week 14.
This is a multi-center, randomized, double-blind, placebo-controlled study.
Participants who meet the entry IPSS inclusion criteria at Week 0 will be randomized and enroll in the double-blind treatment period. Participants will be randomized to one of three treatment arms and will receive two 6-month courses of study drug administered on Days 0 and 14 of each 6-month course. Treatment arms include: ozarelix 30mg + 15mg, ozarelix 15mg + 15mg or placebo + placebo. Safety and efficacy assessments will be performed at defined intervals throughout the study. At Week 52 all participants on study will be eligible to receive ozarelix for two additional courses in the open-label treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria (all must be answered No):
Has the participant taken or is the patient currently taking any of the following:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive Placebo + Placebo on Days 0 and 14 of each 6-month course.
Drug: Placebo
Participants will receive 15 mg Ozarelix + 15 mg Ozarelix on Days 0 and 14 of each 6-month course.
Drug: ozarelix
Participants will receive 30 mg Ozarelix + 15 mg Ozarelix on Days 0 and 14 of each 6-month course.
Drug: ozarelix
One single-dose vial contains 16.5 mg of ozarelix. The drug is reconstituted with 1.3 mL of diluent.
Identical placebo is also provided and reconstituted using diluent containing 0.1% saline solution.
Change From Baseline International Prostate Symptom Score (IPSS) Score at Week 14
IPSS is a validated self-administered index for grading benign prostatic hyperplasia (BPH)-related signs and symptoms. It consists of a set of seven questions. A total score of 1-7 indicates mild disease, 8-19 moderate disease and 20-35 severe disease.
Time frame: Week 14
Change From Baseline IPSS (Including Sub-scores) at Week 52
The International Prostate Symptom Score (IPSS) consists of 7 questions concerning urinary symptoms and 1 question concerning quality of life (QoL) with total score and subscores (voiding, storage and QoL). 1) Voiding- The subscale voiding score is the sum of the responses to 4 voiding symptoms questions (incomplete emptying, intermittency, weak stream, and straining). 2) Storage- The subscale storage score is the sum of the responses to 3 storage symptoms questions (frequency, urgency, and nocturia). Voiding and Storage: the lowest and highest possible scores range from 0 to 15 (mildly symptomatic to severely symptomatic). Voiding and Storage: each question is assigned points from 0 to 5 indicating increasing severity of the particular symptom. And 3) QoL assessment was a single question asking the participant how he would feel about tolerating his current level of symptoms for the rest of his life. The lowest and highest possible score ranges from 0 to 6 (very pleased to terrible).
Time frame: Week 52
Change From Baseline Benign Prostatic Hyperplasia Impact Index (BPHII) Score at Week 14 and Week 52
BPH Impact Index (BII) is used to assess the impact of BPH on various aspects of health. This 4 question self administered index uses a scoring range from 0 (best) to 13 (worst).
Time frame: Weeks 14 and 52
Lower Urinary Tract Symptoms (LUTS) Global Assessment Question (LUTS-GAQ) Response at Week 52
The self administered LUTS GAQ is a "yes" or "no" response to a question asking whether overall improvement in LUTS will be observed during the treatment period.
Time frame: Week 52
Change From Baseline Maximum Urine Flow (Qmax) at Week 14 and Week 52
Qmax was measured by free flow uroflowmetry. Qmax is defined as the peak urine flow rate (measured in milliliter (mL)/second using a standard calibrated flowmeter). For a Qmax to be considered valid, the voided volume had to be at least 125 mL. The uroflowmeter is to be calibrated weekly.
Time frame: Week 14 and Week 52
Change From Baseline International Index of Erectile Function-15 (IIEF-EF) Score at Week 14 and Week 52
IIEF-EF is defined as the sum of the scores for Questions 1-5 and 15 of the IIEF questionnaire. This recall instrument is self-administered by the participant. Individual questions are graded from 1 to 5 with a maximum total score of 30. Lower IIEFEF scores represent diminished erectile function. Men with a score of ≥ 26 are interpreted as having normal erectile function.
Time frame: Week 14 and Week 52
Change From Baseline International Prostate Symptom Score - Quality of Life (IPSS-QOL) at Week 14 and Week 52
IPSS QOL is a disease-specific quality of life question, referred to as IPSS Question 8. Participants with an IPSS QOL of \<3 at screening will be excluded from this study. The rating is as follows: 0=delighted, 1=pleased, 2=mostly satisfied, 3=mixed, 4=mostly dissatisfied, 5=unhappy, 6=terrible.
Time frame: Week 14 and Week 52
Number of Participants With Treatment-Emergent Adverse Events
Time frame: Up to 104 weeks
Ran from Dec 2008 to primary completion in Jan 2010, 13 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ozarelix
Spectrum Pharmaceuticals, Inc →